Clinical Data for HNSCC
Patient no. | Sex | Age (y) | Body weight (kg) | Lesion type | Location of primary tumor | 18F-FDG PET indication | Staging | 18F-FMT dose (MBq) | Specific activity* (GBq/μmol) |
1 | M | 50 | 58 | SCC | Hypopharyngeal | Staging | T4 N2 M0 | 306 | 31.8 |
2 | M | 70 | 75 | SCC | Laryngeal | Staging | T3 N2c M0 | 300 | 25.5 |
3 | M | 67 | 84 | SCC | Oropharynx | Staging | T4 N3 M0 | 304 | 82.2 |
4 | M | 64 | 77 | SCC | Tongue | Staging | T2 N2a M0 | 306 | 38.5 |
5 | M | 68 | 70 | SCC | Oropharynx | Restaging | T3 N2 M0 | 318 | 83.9 |
6 | M | 48 | 113 | SCC | Oropharynx | Staging | T1 N2b M0 | 324 | 57.2 |
7 | M | 44 | 89 | SCC | Oropharynx | Staging | T4 N2c M0 | 303 | 47.4 |
8 | M | 67 | 83 | SCC | Hypopharyngeal | Restaging | T2 N2 M0 | 316 | 38.2 |
↵* Specific activity at time point of injection.
SCC = squamous cell carcinoma.